Blog - Page 69 of 5734 - QualityStocks

MondayJun 22, 2026 12:59 pm

QualityStocksNewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Featured in Audio Editorial on AI Infrastructure Automation Opportunity

Nightfood Holdings (OTCQB: NGTF) operating through its TechForce Robotics division, was featured in a NetworkNewsAudio Audio Press Release highlighting the growing demand for automation solutions driven by the global buildout of artificial intelligence infrastructure. The editorial notes that major technology companies are expected to invest hundreds of billions of dollars in AI-related infrastructure, creating downstream opportunities for companies providing manufacturing, engineering and precision automation systems. Nightfood Holdings was highlighted for expanding its AI-enhanced robotics platform beyond hospitality applications into pharmaceutical automation, laboratory environments, semiconductor-adjacent manufacturing and AI infrastructure support. The editorial also pointed to the company's recently announced strategic alliance with JJ Enterprise as a move aimed at addressing increasing demand for intelligent…

MondayJun 22, 2026 12:32 pm

QualityStocksNewsBreaks – MAX Power Mining Corp. (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) Appoints Chad Levesque as President and Director

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising. MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) announced the appointment of Chad Levesque as president and a member of its board of directors, expanding the company's leadership team as it advances commercial evaluation of its Natural Hydrogen assets in Saskatchewan. Levesque, who has supported MAX Power's capital markets, corporate development and investor relations initiatives since the company became publicly traded in 2022, will continue to lead those efforts while helping broaden awareness of the company's Natural Hydrogen strategy. Figure 1 – Drilling Photo of Lawson Drilling, Genesis…

MondayJun 22, 2026 12:19 pm

QualityStocksNewsBreaks – Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) Publishes Updated Investor Materials Highlighting New Drill Targets

This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising. Nevada Organic Phosphate (CSE: NOP) (OTCQB: NOPFF) announced the publication of an updated corporate fact sheet and investor presentation outlining recently identified drilling locations at its Murdock Mountain Project. The updated materials provide shareholders with new information on exploration targets and their anticipated significance to the company's ongoing exploration program. Nevada Organic Phosphate said the updated fact sheet and presentation include an overview of exploration strategy and progress, summaries of newly identified drilling locations, updated property graphics and a revised capitalization table. The company said the materials are intended to help investors better understand how the…

MondayJun 22, 2026 12:07 pm

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Announces C$5 Million Private Placement to Advance ONC010 Development

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced a non-brokered private placement of 6,764,069 units priced at C$0.7392 per unit for gross proceeds of approximately C$5 million. Each unit consists of one common share and one warrant exercisable at C$0.90 per share for three years. The financing is expected to close on or about July 10, 2026, subject to regulatory approvals, including approval from Cboe Canada. Onco-Innovations said proceeds will be used to advance its ONC010 program through manufacturing and preclinical testing activities, support development of its SynoGraph(TM) platform and provide working capital for general…

MondayJun 22, 2026 11:58 am

QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Advances ONC010 Program With Successful 300-Gram API Scale-Up Batch

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient supporting its proprietary ONC010 drug candidate. The batch, produced as part of Dalton Pharma Services' Process Optimization and Intermediate Scale-Up Program, achieved approximately 99.3% purity with no detectable residual solvents following comprehensive quality control and Certificate of Analysis review, marking an important manufacturing milestone for the company's PNKP inhibitor program. Onco-Innovations said the scale-up campaign demonstrates the reproducibility and scalability of the manufacturing process and is expected to support future…

MondayJun 22, 2026 11:45 am

QualityStocksNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention

VERAXA Biotech (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC(TM)-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity. VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities…

MondayJun 22, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets a $393 Billion Heart Disease Problem with Epigenetics and AI

For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size. What makes Cardio Diagnostics' approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity. The company's recent commercial and regulatory milestones give additional shape to the investment thesis. Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According…

MondayJun 22, 2026 10:30 am

American Fusion(TM) Inc. (AMFN) Expands Patent Portfolio Targeting Future Commercial Texatron(TM) Fusion Engine(TM) Platform

American Fusion has filed a new patent application covering innovations expected to be incorporated into future commercial versions of its Texatron(TM) Fusion Engine(TM) platform. Management believes the technologies disclosed in the filing could ultimately support hundreds of additional patent applications as the platform evolves, with a growing intellectual property portfolio focused on fusion energy generation, plasma control, system architecture, and energy-delivery technologies. Through its wholly owned subsidiary, Kepler Fusion Technologies, American Fusion(TM) is pursuing a modular approach to fusion energy deployment, targeting industrial and commercial customers through behind-the-meter energy deployments before broader grid-scale applications. The company is currently developing multiple…

MondayJun 22, 2026 10:30 am

QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), was featured in a BioMedWire editorial highlighting its development of Lucid-MS, a patented, first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis. Unlike conventional MS treatments that primarily target the immune system, Lucid-MS is being developed as a non-immunomodulatory neuroprotective therapy and is preparing to enter Phase 2 clinical trials following successful Phase 1 safety and tolerability studies. The editorial notes that Lucid-MS has demonstrated the ability to prevent and reverse myelin degradation in preclinical…

MondayJun 22, 2026 10:20 am

QualityStocksNewsBreaks – Greenland Mines Ltd (NASDAQ: GRML) Signs Drilling Contract for 2026 Skaergaard Field Program

Greenland Mines (NASDAQ: GRML) announced it has awarded a diamond drilling contract to Nordisk Fundering A/S for the 2026 field campaign at its 80%-owned Skaergaard precious and critical metals project in southeast Greenland. The planned program will include approximately 7,500 meters of helicopter-supported diamond core drilling aimed at advancing resource categories, collecting additional metallurgical material and supporting geotechnical studies for potential future open-pit development scenarios. Greenland Mines said the integrated campaign will utilize three helicopter-portable drill rigs and will generate geological, metallurgical and engineering data to support mine planning and broader development studies. The company noted that Nordisk Fundering's Arctic…

Site Search

Company Search